In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...

By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...

Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

There was some good news in the clinical sphere for Gilead Sciences ( GILD 2.74%) on Thursday, and this drove its stock price ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, ...

Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...